Principal Financial Group
AVIR icon

Principal Financial Group’s Atea Pharmaceuticals AVIR Stock Holding History

Principal Financial Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,425
Closed -$37.8K – 2243
2024
Q2 		$37.8K Sell
11,425
-13,949
-55% -$52K ﹤0.01% 2307
2024
Q1 		$103K Sell
25,374
-2,088
-8% -$8.17K ﹤0.01% 2274
2023
Q4 		$83.8K Sell
27,462
-2,930
-10% -$8.87K ﹤0.01% 2288
2023
Q3 		$91.2K Buy
30,392
+4,574
+18% +$15.6K ﹤0.01% 2297
2023
Q2 		$96.6K Buy
25,818
+3,626
+16% +$13.6K ﹤0.01% 2294
2023
Q1 		$74.3K Buy
22,192
+2,644
+14% +$10.7K ﹤0.01% 2335
2022
Q4 		$94K Buy
19,548
+2,041
+12% +$10.3K ﹤0.01% 2299
2022
Q3 		$100K Buy
17,507
+4,181
+31% +$32K ﹤0.01% 2334
2022
Q2 		$94K Buy
+13,326
New +$91K ﹤0.01% 2399
2021
Q4 		– Sell
-6,080
Closed -$213K – 2539
2021
Q3 		$213K Buy
+6,080
New +$169K ﹤0.01% 2415

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Principal Financial Group's AVIR Position: Q3 2024 in Review

Principal Financial Group sold out of Atea Pharmaceuticals (AVIR) in Q3 2024, closing a stake of 11,425 shares — an estimated $37.8K sold.

Principal Financial Group first reported a position in AVIR in Q3 2021 and held it in 10 quarters. The position peaked at $213K in Q3 2021. 108 funds tracked by Wall St. Rank hold AVIR as of Q3 2024.

  • Principal Financial Group reported no remaining Atea Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 11,425 Atea Pharmaceuticals shares in Q3 2024, an estimated $37.8K.
  • Principal Financial Group first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 10 quarters.
  • Principal Financial Group's Atea Pharmaceuticals position peaked at $213K in Q3 2021.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.